What is claimed is:

1. Use of a human milk fortifier composition comprising a human protein constituent from about 35 to about 45 mg/ml and a human fat constituent from about 80 to about 100 mg/ml for the manufacture of a medicament for providing nutrition to a subject who is about to undergo or has undergone surgery, wherein the subject is a full-term infant.
2. The use of claim 1, wherein the human milk fortifier composition comprises a human protein constituent from about 37 to about 42 mg/ml and a human fat constituent from about 86 to about 94 mg/ml.
3. The use of claim 1 or 2, wherein the human milk fortifier composition comprises a human protein constituent from about 35 to about 42 mg/ml protein and a human fat constituent from about 84 to about 95 mg/ml.
4. The use of any one of claims 1-3, wherein the human milk fortifier composition can further comprise one or more constituents selected from the group consisting of: calcium, chloride, copper, iron, magnesium, manganese, phosphorus, potassium, selenium, sodium, and zinc.
5. Use of a fortified human milk composition for the manufacture of a medicament for providing nutrition to a subject who is about to undergo or has undergone surgery, wherein the fortified human milk composition comprises human milk and human milk fortifier; wherein the fortified human milk composition comprises a human protein constituent from about 10 to about 30 mg/ml protein and a human fat constituent from about 40 to about 70 mg/ml fat; and wherein the subject is a full-term infant.
6. The use of claim 5, wherein the fortified human milk composition can further comprise one or more constituents selected from the group consisting of: calcium, chloride, copper, iron, magnesium, manganese, phosphorus, potassium, selenium, sodium, and zinc.
7. The use of any one of claims 1-6, wherein the subject has undergone surgery.
8. The use of any one of claims 1-7, wherein one or more clinical outcomes are improved in the subject.
9. The use of claim 8, wherein the one or more improved clinical outcomes comprises improved neurodevelopmental outcomes, improved growth velocity including rate of weight gain, incremental linear growth, incremental rate of head circumference growth, reduced length of stay in the hospital and/or a reduction of the days of parenteral nutrition.

10. The use of claim 8 or 9, wherein the one or more improved clinical outcomes comprises a reduced incidence of feeding intolerance, sepsis, necrotizing enterocolitis (NEC), wound infection and/or wound dehiscence.
11. The use of any one of claims 1-10, wherein the infant is 7 days old or younger.
12. The use of any one of claims 1-11, wherein the surgery is performed to correct a congenital heart defect.
13. The use of claim 12, wherein the congenital heart defect is single ventricle physiology.
14. The use of claim 12, wherein the congenital heart defect is hypoplastic left heart syndrome.
15. The use of any one of claims 1-11, wherein the surgery is performed to correct a congenital intestinal defect.
16. The use of claim 15, wherein the congenital intestinal defect comprises gastroschisis or omphalocele.